文献速递创伤与烧伤复苏、休克与脓毒症

氨甲环酸与大血管损伤修复术后血栓相关再干预率升高无关

Tranexamic acid is not associated with a higher rate of thrombotic-related reintervention after major vascular injury repair.
PubMed 文献 · J Trauma Acute Care Surg · 2023-12-08
一句话结论PROOVIT登记研究显示,大血管损伤修复患者使用氨甲环酸未增加血栓相关技术失败风险,多因素校正后TXA与再干预、再手术及血栓事件均无显著关联。

该研究基于PROOVIT登记数据库(2013—2022年),纳入接受开放或腔内修复的大血管损伤患者,比较使用氨甲环酸(TXA组297例)与未使用(非TXA组1941例)患者血栓相关技术失败(TRTF)的发生率。TXA组入院时低血压比例、持续血管升压药需求、24小时内浓缩红细胞输注量及冷沉淀使用率更高,干预期间抗凝药使用率更低。单因素分析中TXA组即刻再手术率和总体再手术率显著更高,但多因素校正损伤类型、升压药、血制品及抗凝药使用和血流动力学后,TXA与即刻再干预(OR 1.19,95%CI 0.75-1.88,p=0.465)、总体再手术(OR 1.33,95%CI 0.82-2.17,p=0.249)及修复血管血栓事件(OR 1.07,95%CI 0.60-1.92,p=0.806)均无显著关联。TRTF两组无差异(6.3% vs 3.8%,p=0.141)。结论认为TXA不增加大血管损伤修复术后血栓相关技术失败风险,但需进一步前瞻性研究探讨剂量依赖或时间依赖关联。

要点

  • 多因素校正后,TXA与即刻再干预(OR 1.19,95%CI 0.75-1.88,p=0.465)、总体再手术(OR 1.33,95%CI 0.82-2.17,p=0.249)及修复血管血栓事件(OR 1.07,95%CI 0.60-1.92,p=0.806)均无显著关联。
  • 血栓相关技术失败(TRTF)发生率TXA组6.3% vs 非TXA组3.8%(p=0.141),两组无显著差异。
  • 单因素分析中TXA组即刻再手术率(10.1% vs 5.7%,p=0.006)和总体再手术率(11.4% vs 7%,p=0.009)显著更高,但校正混杂后关联消失。
  • TXA组入院时低血压(33.6% vs 11.5%,p<0.001)、持续升压药需求(41.4% vs 18.4%,p<0.001)及24小时内浓缩红细胞输注量(3.2 vs 2.0单位,p<0.001)均更高。
  • TXA组冷沉淀使用率更高(9.1% vs 2%,p<0.001),干预期间抗凝药使用率更低(32.7% vs 43.8%,p<0.001),因子VII使用率两组无差异(1% vs 0.7%,p=0.485)。

适用人群与场景

  • PROOVIT登记数据库中2013—2022年因大血管损伤接受开放或腔内修复的患者。
  • TXA组297例,非TXA组1941例;两组人口学、损伤类型和干预方式相似。

研究设计与关键结果

  • 研究类型:基于PROOVIT前瞻性观察性血管损伤治疗登记数据库的查询分析,纳入2013—2022年因大血管损伤接受开放或腔内修复的患者。
  • TXA组(n=297)与非TXA组(n=1941)比较:入院时低血压33.6% vs 11.5%(p<0.001),持续血管升压药需求41.4% vs 18.4%(p<0.001),24小时内浓缩红细胞输注3.2 vs 2.0单位(p<0.001)。
  • TXA组冷沉淀使用率9.1% vs 2%(p<0.001),干预期间抗凝药使用率32.7% vs 43.8%(p<0.001),因子VII使用率1% vs 0.7%(p=0.485)。
  • 血栓相关技术失败(TRTF)发生率TXA组6.3% vs 非TXA组3.8%(p=0.141)。
  • 单因素分析:TXA组即刻再手术率10.1% vs 5.7%(p=0.006),总体再手术率11.4% vs 7%(p=0.009)。
  • 多因素校正损伤类型、升压药输注、血制品及抗凝药使用和血流动力学后:即刻再干预OR 1.19(95%CI 0.75-1.88,p=0.465),总体再手术OR 1.33(95%CI 0.82-2.17,p=0.249),修复血管血栓事件OR 1.07(95%CI 0.60-1.92,p=0.806),均无显著关联。

证据类型、等级与局限

  • 证据类型:基于PROOVIT前瞻性观察性登记数据库的观察性研究;证据等级:治疗/护理管理,Level IV。
  • 局限:原文未报告局限性;结论指出需进一步前瞻性研究探讨TXA与大血管损伤中血栓事件的剂量依赖或时间依赖关联。

对床旁实践的改变

  • 在大血管损伤修复患者中,使用TXA未与血栓相关技术失败风险升高相关,多因素校正后再干预、再手术及修复血管血栓事件均无显著关联。
  • 作者认为需进一步前瞻性研究探讨TXA与大血管损伤中血栓事件的剂量依赖或时间依赖关联。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Tranexamic acid (TXA) is associated with lower mortality and transfusion requirements in trauma patients, but its role in thrombotic complications associated with vascular repairs remains unclear. We investigated whether TXA increases the risk of thrombosis-related technical failure (TRTF) in major vascular injuries (MVI).

METHODS: The PROspective Observational Vascular Injury Treatment (PROOVIT) registry was queried from 2013 to 2022 for MVI repaired with an open or endovascular intervention. The relationship between TXA administration and TRTF was examined.

RESULTS: The TXA group (n = 297) had higher rates of hypotension at admission (33.6% vs. 11.5%, p < 0.001), need for continuous vasopressors (41.4% vs. 18.4%, p < 0.001), and packed red blood cell transfusion (3.2 vs. 2.0 units, p < 0.001) during the first 24 hours compared with the non-TXA group (n = 1941), although demographics, injury pattern, and interventions were similar. Cryoprecipitate (9.1% vs. 2%, p < 0.001), and anticoagulant administration during the intervention (32.7% vs. 43.8%, p < 0.001) were higher in the TXA group; there was no difference in the rate of factor VII use between groups (1% vs. 0.7%, p = 0.485). Thrombosis-related technical failure was not different between the groups (6.3% vs. 3.8 p = 0.141) while the rate of immediate need for reoperation (10.1% vs. 5.7%, p = 0.006) and overall reoperation (11.4% vs. 7%, p = 0.009) was significantly higher in the TXA group on univariate analysis. There was no significant association between TXA and a higher rate of immediate need for reintervention (odds ratio [OR], 1.19; 95% confidence interval [CI], 0.75-1.88; p = 0.465), overall reoperation rate (OR, 1.33; 95% CI, 0.82-2.17; p = 0.249) and thrombotic events in a repaired vessel (OR, 1.07; 95% CI, 0.60-1.92; p = 0.806) after adjusting for type of injury, vasopressor infusions, blood product and anticoagulant administration, and hemodynamics.

CONCLUSION: Tranexamic acid is not associated with a higher risk of thrombosis-related technical failure in traumatic injuries requiring major vascular repairs. Further prospective studies to examine dose-dependent or time-dependent associations between TXA and thrombotic events in MVIs are needed.

LEVEL OF EVIDENCE: Therapeutic/Care Management; Level IV.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Asaadi S, Mukherjee K, Abou-Zamzam AM, et al. Tranexamic acid is not associated with a higher rate of thrombotic-related reintervention after major vascular injury repair. J Trauma Acute Care Surg. 2023. PMID: 38079274. doi:10.1097/TA.0000000000004227

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。